Gilead Sciences

Healthcare

Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal

Photo via Andre M. Chang/ZUMAPRESS/Newscom

Soleno Therapeutics’s Vykat XR is the first drug to be approved for treating the insatiable hunger caused by Prader-Willi Syndrome.

1 min read

Photo via Yichuan Cao/Sipa USA/Newscom

Healthcare

Gilead Strikes $7.8 Billion Deal for Control of Cancer Biotech Arcellx

The pharma giant already held an 11.5% stake as part of a 2022 effort to co-develop and co-commercialize the cancer treatment anito-cel.

2 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.